• LTR Pharma and Restorative Sexual Health Clinic to launch new men’s online healthcare platform
• Platform to offer medical consultations, therapeutic services and prescription treatments
• Platform forecast to launch in Q1 CY25, positioning LTR Pharma in burgeoning telehealth market

Special Report: LTR Pharma has inked a deal with a leading men’s healthcare group to establish an online men’s health platform to provide Aussie men with convenient access to healthcare professionals, therapeutic services and prescription treatments.

LTR Pharma (ASX:LTP) has announced it has entered a strategic joint venture with the privately-owned Restorative Sexual Health Clinic (RSHC) to establish a men’s health platform, which will see it capitalise on the rapidly growing telehealth market.

The JV brings together LTP’s pharmaceutical expertise and RSHC’s established clinical experience in men’s sexual health.

Expected to launch in Q1 CY25, the platform will deliver healthcare services directly to Australian men and offer a range of services including:

• Medical consultations
• Therapeutic services
• Prescription and non-prescription treatments
• Integrated health management solutions

Growth market

LTP said the global telehealth market was valued at over US$140bn in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 22% to 2032.

The growth is being driven by increasing smartphone adoption, improved internet connectivity, and the growing acceptance of digital health solutions.

In the US telehealth adoption shows strong momentum, with Australia mirroring these trends and a rising acceptance of telehealth for men’s health consultations.

SPONTAN ED treatment

LTP has been working alongside the RSHC, with the organisation prescribing its novel proprietary PDE5 nasal spray treatment for erectile dysfunction (ED) SPONTAN.

In August, LTP announced first patients were prescribed SPONTAN by the RSHC under Australia’s Therapeutic Goods Administration’s Special Access Scheme (SAS).

The TGA’s SAS enables health practitioners to access unapproved therapeutic goods for individual patients, assessed on a case-by-case basis.

SPONTAN is considered a game-changer in the treatment of ED. A pivotal trial has demonstrated it outperformed traditional oral erectile dysfunction medications with faster onset, providing patients with greater spontaneity in their intimate relationships along with greater convenience.

Significant milestone for future growth

LTR Pharma chairman Lee Rodne said the JV represented a significant milestone in LTP’s strategic commercialisation plan.

“By partnering with a leader in men’s health services, we are well-positioned to meet the growing demand for accessible healthcare solutions,” he said.

“The platform will offer a discreet and convenient channel for men to access professional healthcare services and prescribed treatments.”

RSHC founder and sexologist Melissa Hadley Barrett said the partnership aligned perfectly with its mission to provide comprehensive, evidence-based care that enhances men’s well-being.

“The online platform will expand access to our professional services while maintaining the high standards of care that define our face-to-face clinic,” she said.

“We look forward to working with LTR Pharma to deliver innovative healthcare solutions that make a meaningful difference in men’s lives.”

This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.

 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.